CDK9 inhibitors such as KB-0742 have recently entered clinical trials (e.g., Phase I/II trial NCT04718675), with preliminary pharmacodynamic data showing effective reduction of MYC expression in preclinical cancer models. The gene discussed is MYC; the disease is cancer.